Skip to Content

'
Jan A. Burger, M.D., Ph.D

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

"Privatdozent" (lecturer) in Internal Medicine, Albert-Ludwigs University, School of Medicine, Freiburg, Germany
Faculty, Graduate School of Biomedical Sciences, University of Texas-Houston Health Science Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 428
Houston, TX 77030-4009
Room Number: Department of Leukemia, FC4.3032
Phone: 713-563-1487
Email: jaburger@mdanderson.org

Education & Training

Degree-Granting Education

1994 Albert Ludwigs University, School of Medicine, Freiburg, Germany, M.D., Ph.D., Magna cum laude, Medicine

Postgraduate Training

11/1999-9/2005 Fellowship, Instructor, Hematology/Oncology, Freiburg University Hospital, Freiburg, Germany, Professor Roland Mertelsmann
11/1996-10/1999 Postdoctoral Fellow, Hematology/Oncology, University of California, San Diego, San Diego, CA, Dr. Thomas J. Kipps
1/1995-10/1996 Residency, Internal Medicine, Freiburg University Hospital, Freiburg, Germany, Professor Roland Mertelsmann

Board Certifications

9/2005 Hematology/Oncology ("Schwerpunkt Hamatologie und Internistische Onkologie"). Landesaertztekammer Baden-Wurttemberg, Germany
5/2005 Internal Medicine ("Facharzt fur Innere Medizin"), Landesaerztekammer Baden-Wurttemberg, Germany
7/1996 Medical Board Licensing Certificate ("Approbation als Arzt")

Experience/Service

Academic Appointments

Assistant Professor, tenure track, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2005-8/2011
Director, Diagnostic Flow Cytometry Laboratory, Hematology/Oncology, Freiburg University, Freiburg, Germany, 2002-2005
Instructor and Fellow in Internal Medicine and Hematology/Oncology, Department of Internal Medicine, Freiburg University, Freiburg, Germany, 11/1999-9/2005
Postdoctoral Fellowship, Hematology/Oncology, University of California, San Diego (PI: Thomas J. Kipps, MD, PhD), San Diego, CA, 11/1996-10/1999
Medical Residency, Department of Internal Medicine, Division of Internal Medicine, Freiburg University Hospital, Professor Roland Mertelsmann, Freiburg, Germany, 1/1995-10/1996

Institutional Committee Activities

Reviewer and Member; "Excellent Protocol Reviewer" in 2006, CRC, 2006-2011

Honors and Awards

2007 ASCO Career Development Award (CDA), ASCO
2006 ASCO Young Investigators Award (YIA), ASCO
2006 Kimmel Scholar Award, Sidney Kimmel Foundation for Cancer Research
2006 New Investigator Award, Leukemia Research Foundation
2006 Venia Legendi in Internal Medicine ("Privatdozent"), Albert-Ludwigs-University Freiburg, Freiburg, Germany
2001 Arthur Pappenheim Award, German Hematology Society (DGHO) for research in the field of hematology/CLL
1996-1998 Research Fellowship: Postdoctoral fellowship, The University of California, San Diego by the Deutsch Krebshilfe, Bonn, Germany
1994 Doctoral thesis: "The effects of peritonitis exudates on the chemotaxis of human neutrophils", degree "magna cum laude", Department of Surgery, 12/1994, Albert Ludwigs University of Medicine, Freiburg, Germany

Professional Memberships

American Association for Cancer Research (AARC)
Member, 2007-present
American Society of Clinical Oncology (ASCO)
Member, 2005-present
American Society of Hematology (ASH)
Member, 1997-present
German Society of Hematology/Oncology (Deutsche Gesellschaft fur Hamatologie und Onkologie/DGHO)
Member, 2000-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Burger JA. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 24(6):643-9, 11/2012. e-Pub 9/2012. PMID: 22960555.
2. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger JA, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 9/2012. e-Pub 1/2012. PMID: 22282348.
3. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 26(8):1812-20, 8/2012. e-Pub 3/2012. PMID: 22460735.
4. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 8/2012. e-Pub 4/2012. PMID: 22534616.
5. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-83, 7/2012. e-Pub 2/2012. PMID: 22362000.
6. Eghtedar A, Verstovsek S, Estrov Z, Burger JA, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 5/2012. e-Pub 3/2012. PMID: 22422826.
7. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13(71):287-97, 4/2012. PMID: 22541616.
8. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 IL-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97(4):599-607, 4/2012. e-Pub 11/2011. PMCID: PMC3347674.
9. Peled A, Wald O, Burger JA. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21(3):341-53, 3/2012. e-Pub 1/2012. PMID: 22283809.
10. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 14(3):276-86, 3/2012. e-Pub 2/2012. PMCID: PMC3290742.
11. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-9, 2/2012. e-Pub 12/2011. PMID: 22180443.
12. Davids MS, Burger JA. Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol 3(S1), 2012. e-Pub 2/2012. PMCID: PMC3404599.
13. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger JA, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 12/2011. e-Pub 7/2011. PMID: 21733558.
14. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 29(31):4088-95, 11/2011. e-Pub 10/2011. PMID: 21969505.
15. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger JA, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-23, 10/2011. e-Pub 8/2011. PMID: 21821712.
16. Burger JA, Hoellenriegel J. Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia. Oncotarget 2(10):737-8, 10/2011. e-Pub 10/2011. PMCID: PMC3248155.
17. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489-98, 9/2011. e-Pub 7/2011. PMID: 21725050.
18. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603-12, 9/2011. e-Pub 7/2011. PMID: 21803855.
19. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger JA, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-8, 8/2011. e-Pub 7/2011. PMID: 21750315.
20. Burger JA, Sivina M, Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma 52 Suppl 2:94-8, 6/2011. e-Pub 3/2011. PMID: 21438839.
21. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 117(5):1662-9, 2/2011. e-Pub 11/2010. PMID: 21115978.
22. Burger JA. Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia. Hematology Am Soc Hematol Educ Program 2011:96-103, 2011. PMID: 22160019.
23. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Semin Cancer Biol 20(6):424-30, 12/2010. e-Pub 9/2010. PMID: 20883788.
24. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger JA, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-2077, 9/2010. e-Pub 5/2010. PMID: 20466853.
25. Quiroga MP, Burger JA. BCR-Mediated Decrease of CXCR4 and CD62L in CLL - Letter. Cancer Res 70(12):5194; author reply 5195, 6/2010. e-Pub 5/2010. PMID: 20501831.
26. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger JA, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2/2010. e-Pub 11/2009. PMID: 19895616.
27. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis. Blood 114(20):4441-50, 11/2009. e-Pub 9/2009. PMID: 19762485.
28. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114(16):3367-75, 10/2009. e-Pub 7/2009. PMID: 19636060.
29. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 9/2009. e-Pub 6/2009. PMID: 19567878.
30. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 8/2009. e-Pub 6/2009. PMID: 19517462.
31. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood 114(5):1029-37, 7/2009. e-Pub 6/2009. PMID: 19491390.
32. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22):5549-57, 5/2009. e-Pub 3/2009. PMID: 19318683.
33. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113(19):4604-13, 5/2009. e-Pub 2/2009. PMID: 19228923.
34. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger JA, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients with Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 4/2009. e-Pub 2/2009. PMID: 19224852.
35. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-Level Expression of the T Cell Chemokines CCl3 and CCL4 by Chronic Lymphocytic Leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood 113(13):3050-8, 3/2009. e-Pub 12/2008. PMID: 19074730.
36. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B-cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113(1):149-53, 1/2009. e-Pub 10/2008. PMCID: PMC2614629.
37. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23(1):43-52, 1/2009. e-Pub 11/2008. PMID: 18987663.
38. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger JA, Cortes J. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-42, December 15, 2008, 12/2008. PMID: 18818391.
39. Berg T, Fliegauf M, Burger JA, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica 93(11):1728-33, 11/2008. PMID: 18790797.
40. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia. Blood 110(9):3316-3325, 11/2007. e-Pub 7/2007. PMID: 17652619.
41. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137(4):288-96, 5/2007. PMID: 17456052.
42. Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in Acute Myelogenous Leukemia. Blood 109(2):786-791, 1/2007. e-Pub 8/2006. PMID: 16888090.
43. Burger JA, Schmitt-Gräff A, Bürkle A, Seiler L, Finke J. Imatinib Mesylate-induced long-term Remission in Extramedullary T Cell Lymphoid Blastic Phase of Chronic Myelogenous Leukemia. Leuk Lymphoma 47(11):2427-30, 11/2006. PMID: 17107924.
44. Bossaller L,Burger JA, Draeger R, Grimbacher B, Knoth R, Plebani A, Durandy A, Baumann U, Schlesier M, Welcher AA, Peter HH, Warnatz K. ICOS deficiency is associated with a severe reduction of CCR5+ germinal center helper T cells. J Immunol 177:4927-32, 10/2006.
45. Burger JA, Kipps TJ. CXCR4, a key receptor in the cross-talk between tumor cells and their microenvironment. Blood 107(5):1761-7, 3/2006. e-Pub 11/2005. PMID: 16269611.
46. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. Small Peptide Inhibitors of the CXCR4 Chemokine Receptor (CD184) Antagonize the Activation, Migration and Antiapoptotic Responses of CXCL12 in CHronic Lymphocytic Leukemia B Cells. Blood 106(5):1824-30, 9/2005. e-Pub 5/2005. PMID: 15905192.
47. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24(27):4462-71, 6/2005. PMID: 15806155.
48. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3 dependent pathway. Oncogene 24(12):2067-2075, 3/2005. PMID: 15688008.
49. Zeiser R, Mikesch K, Fisch P, Schaefer HE, Burger JA. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol 125(6):679, 6/2004. PMID: 15180856.
50. Hartmann TN, Burger M, Burger JA. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer. J Biol Regul Homeost Agents 18(2):126-130, Apr-Jun, 4/2004. PMID: 15471215.
51. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22(50):8093-8101, 11/2003. PMID: 14603250.
52. Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta 1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudomperipolesis). Br J Haematol 122(4):579-589, 8/2003. PMID: 12899713.
53. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstädt H. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 168(12):6244-6252, 6/2002. PMID: 12055238.
54. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 43(3):461-466, 3/2002. PMID: 12002747.
55. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 99(3):1030-1037, 2/2002. PMID: 11807009.
56. Aivado M, Schulte K, Henze L, Burger JA, Finke J, Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 29(4 Suppl 13):19-22, 2002.
57. Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. Immunostimulatory DNA inhibits IL-4 dependent lgE synthesis by human B cells. J Allergy Clin Immunol 108(3):417-423, 9/2001. PMID: 11544462.
58. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 107(3):305-15, 2/2001. PMCID: PMC199194.
59. Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocytemacrophage colony-stimulating factor and CD 154 enhance the immune response to genetic vaccines. Vaccine 19(15-16):2181-2189, 2/2001. PMID: 11228391.
60. Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol 108(3):641-652, 3/2000. PMID: 10759724.
61. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, Maini RN. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2(6):477-488, 2000. e-Pub 8/2000. PMCID: PMC17820.
62. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94(11):3658-3667, 12/1999. PMID: 10572077.
63. Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol 163(4):2017-2022, 8/1999. PMID: 10438939.
64. Sach M, Burger JA, Engelhardt A, Ketelsen UP, Schollmeyer P. [Temporary hemiparesis and Raynaud symptoms in eosinophilic fasciitis]. Internist (Berl) 38(7):688-91, 7/1997. PMID: 9333603.
65. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11(2):281-3, 2/1997. PMID: 9009093.
66. Sach M, Bauermeister K, Burger JA, Loetscher P, Elsner J, Schollmeyer P, Dobos GJ. Inverse MCP-1/L-8 ratio in effluents of CAPD patients with peritonitis and in isolated cultured human peritoneal macrophages. Nephrol Dial Transplant 12(2):315-320, 2/1997. PMID: 9132652.
67. Burger JA, Ochs A, Wirth K, Berger DP, Mertelsmann R, Engelhardt R, Roessle M, Haag K. The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol 8(2):200-202, 2/1997. PMID: 9093733.
68. Burger JA, Schöffel U, Sach M, Jacobs E, Kownatzki E, von Specht BU, Farthmann EH. Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. Eur J Surg 161(9):647-53, 9/1995. PMID: 8541423.

Editorials

1. Burger JA. Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leuk Lymphoma 53(1):3-4, 1/2012. e-Pub 9/2011. PMID: 21830996.
2. Burger, JA . Angiopoietin-2 in CLL. Blood 116(4):508-09, 7/2010.
3. Burger JA. CXCR4 in acute myelogenous leukemia (AML): When too much attraction is bad for you. Leuk Res 18(4):747-48, 6/2009. e-Pub 12/2008. PMID: 19091405.
4. Burger JA and Gandhi V. Tissue microenvironments and drug resistance in Chronic Lymphocytic Leukemia: ABT-737 must overcome the same hurdles as our older drugs. Faculty 1000 Medicine, 6/2009.
5. Burger, JA . Fledgling prognostic markers in CLL. Blood 110(12):3820-21, 12/2007.
6. Burger JA. No cell is an island unto itself: The stromal microenvironment in chronic lymphocytic leukemia. Leuk Res 31(7):887-8, 7/2007. e-Pub 1/2007. PMID: 17234265.

Abstracts

1. Jabbour E, Garcia-Manero G, Ghanem HA, Ravandi F, Faderl S, Cortes JE, Reyes AS, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Kantarjian HM. A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS. Blood (ASH Annual Meeting Abstracts) 116 (#2188), 11/2010.
2. Ponader S, Buggy J, O'Brien S, Wierda WG, Keating M, Burger JA. Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo. Blood (ASH Annual Meeting Abstracts) 116 (#45), 11/2010.
3. Jabbour E, Kantarjian H, Cornelison AM, Kadia T, Welch MA, Abruzzo LV, Burger JA, Ferrajoli A, Garcia-Manero G, Cortes JE. Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML). Blood (ASH Annual Meeting Abstracts) 116 (#1232), 11/2010.
4. Thomas DA, O'Brien S, Cortes JE, Faderl S, Wierda WG, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger JA, Garris R, Romaguera J, Hagemeister F, Kantarjian H. Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. Blood (ASH Annual Meeting Abstracts) 116 (#1781), 11/2010.
5. Frenzel LP, Schulz A, Pallasch CP, Claus R, Ponader S, Burger JA, Hallek M, Plass C, Wendtner CM. Microenvironment Influences Expression of TOSO – a Novel NF-Kappa B Target Gene In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#695), 11/2010.
6. Eghtedar A, Verstovsek S, Cortes JE, Estrov Z, Burger JA, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Newton R, Kantarjian H, Ravandi F. Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML). Blood (ASH Annual Meeting Abstracts) 116 (#509), 11/2010.
7. Hoellenriegel J, Meadows SA, Wierda WG, Keating MJ, Lannutti B, Burger JA. Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurselike Cells (NLC), In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#116), 11/2010.
8. Andritsos L, Byrd JC, Jones JA, Hewes B, Kipps TJ, Hsu FJ, Burger JA. Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#2450), 11/2010.
9. Badoux X, Al-Ameri AM, O'Brien S, Wierda WG, Burger JA, Faderl S, Estrov Z, Lerner S, Keating M, Ferrajoli A. Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL. Blood (ASH Annual Meeting Abstracts) 116 (#4638), 11/2010.
10. Hoellenriegel J, Coffey G, Sinha U, Pandey A, Wierda WG, Keating MJ, Burger JA. Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#3604), 11/2010.
11. Sivina M, Hartmann E, Boucas J, Keating MJ, Wierda WG, Herling M, Rosenwald A, Burger JA. Stroma-Induced TCL1 Expression In Chronic Lymphocytic Leukemia Cells Is Associated with Down Regulation of TCL1A-Targeting miRNAs. Blood (ASH Annual Meeting Abstracts) 116 (#52), 11/2010.
12. Burger JA, O'Brien S, Fowler N, Advani R, Sharman JP, Furman RR, Izumi R, Buggy J, Loury D, Hamdy A, Byrd JC, Blum CA. The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. Blood (ASH Annual Meeting Abstracts) 116 (#57), 11/2010.
13. Parikh SA, Wierda WG, Badoux X, O'Brien SM, Ferrajoli A, Faderl S, Burger JA, Lerner S, Kantarjian H, Keating MJ. Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). J Clin Oncol (2010 ASCO Annual Meeting) 28(7) (#6519), 6/2010.
14. Vigil CE, Kantarjian H, Thomas DA, O'Brien SM, Ravandi Kashani F, Koller, CA, Burger JA, Garris RS, Baccus MD, Faderl S. Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL). J Clin Oncol (2010 ASCO Annual Meeting) 28((15)) (#6524), 6/2010.
15. Sivina M, Hartmann E, Krupnik D, LaPushin R, Keating M, Kipps T, Rosenwald A, Wierda W, Burger JA. CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment. Blood (ASH Annual Meeting Abstracts) 114(22):151 (#358), 11/2009.
16. Thomas D, Kantarjian H, Faderl S, Wierda W, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau S, Andreeff M, Garris R, Keating M, O'Brien S. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood (ASH Meeting Abstracts) 114(22):344-345 (#836), 11/2009.
17. Badoux X, Keating M, O'Brien S, Kadia T, Ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda W. Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114(22):1332-1333 (#3431), 11/2009.
18. Badoux X, Ramos C, Harris D, Li P, Liu Z, Burger JA, O'Brien S, Ferrajoli A, Keating M, Estrov Z. Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3. Blood (ASH Annual Meeting Abstracts) 114(22):511 (#1242), 11/2009.
19. Sivina M, Hartmann E, Keating M, Wierda W, Rosenwald A, Burger JA. Marrow Stromal Cells Induce TCL1 Expression in Chronic Lymphocytic Leukemia B Cells. Blood (ASH Annual Meeting Abstracts) 114(22):927 (#2347), 11/2009.
20. Badoux X, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo L, Wierda W. Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. Blood (ASH Annual Meeting Abstracts) 114(22):513-514 (#1248), 11/2009.
21. Ravandi F, Kantarjian H, Thomas D, Faderl S, Jones D, Koller C, Dara S, Garris R, Kebriaei P, Champlin R Borthakur G, Wierda W, Burger JA, Cortes J, O'Brien S. Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 114(22):345 (#837), 11/2009.
22. Garcia-Manero G, Tambaro F, Bekele F, Jabbour E, Ravandi F, Yang H, Borthakur G, Kadia T, Cortes J, Faderl S, Konopleva M, Pierce S, Burger JA, Estrov Z, O'Brien S, Thomas D, Newsome W, Kantarjian H. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 114(22):436 (#1055), 11/2009.
23. Batty N, Badoux X, Keating M, Lerner M, O'Brien S, Ferrajoli A, Kadia T, Burger JA, Faderl S, Wierda W. Pretreatment Factors Associated with Second Malignancies Occurring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114(22):1339-1340 (#3448), 11/2009.
24. Kurtova A, Sivina M, Quiroga M, Wierda W, Keating MJ, Burger JA. The Immunophenotype Signature CD49d+CD38+ Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells. Blood (ASH Annual Meeting Abstracts) 114(22):150-151 (#356), 11/2009.
25. Schmitt-Graeff A, Bertz H, Metzger M, Strahm B, Stein H, Burger JA. Analysis of Clinico-Pathologic Features and Stromal Cell-Derived Factor (SDF)-1/CXCR4 in Myeloid Sarcoma. Blood (ASH Annual Meeting Abstracts) 112 (#3975), 11/2008.
26. Manshouri T, Estrov Z, Burger JA, Livun A, Zhang Y, Ma S, Gaikwad A, Harris D, Kantarjian H, Verstovsek S. Bone Marrow Stromal Cells Reverse Proapoptotic Effects of JAK2 Inhibitor Atiprimod in Cells Carrying the JAK2V617F mutation. Blood (ASH Annual Meeting Abstracts) 112 (#3738), 11/2008.
27. Wierda W, O’Brien S, Faderl S, Ferrajoli A, Koller C, Estrov Z, Burger JA, Lerner S, Kantarjian H, Keating, M. CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p. Blood (ASH Annual Meeting Abstracts) 112 (#2095), 11/2008.
28. Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen J, Konopleva M, Burger JA, Ferrajoli A, George S, Kantarjian H. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting Abstracts) 112 (#2985), 11/2008.
29. Faderl S, Thomas D, Koller C, Ravandi F, Burger JA, O’Brien S, Dara S, Kantarjian H. Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 112 (#3960), 11/2008.
30. Quiroga M, Kurtova A, Wierda W, Keating M, Burger JA. Inhibition of BCR Signaling Using the SYK Inhibitor R406 Antagonizes Migratory and Pro-Survival Responses in CLL Cells. Blood (ASH Annual Meeting Abstracts) 112 (#2064), 11/2008.
31. Henderson J, O’Brien S, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Tam C, Burger JA, Abruzzo L, Schlette E, Lerner S, Keating M, Wierda W. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment. Blood (ASH Annual Meeting Abstracts) 112 (#2078), 11/2008.
32. Wierda W, O’Brien S, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Cortes J, Tam C, Burger JA, Abruzzo L, Schlette E, Lerner S, Keating M. Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. Blood (ASH Annual Meeting Abstracts) 112 (#2094), 11/2008.
33. Kurtova A, Tamayo A, Ford, Jr. R, Burger JA. Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can Be Diminished by Blocking of VLA-4 and CXCR4 Receptors. Blood (ASH Annual Meeting Abstracts) 112 (#2825), 11/2008.
34. Thomas D, Kantarjian H, Faderl S, Wierda W, Ferrajoli A, Burger JA, Cortes J, Koller C, Borthakur G, Estrov Z, Konopleva M, Ravandi F, Garcia- Manero G, O’Brien S. Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 112 (#1931), 11/2008.
35. Ravandi F, Thomas D, Kantarjian H, Faderl S, Koller C, Dara S, Garris R, Kebriaei P, Borthakur G, Wierda W, Burger JA, Cortes J, O’Brien S. Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 112 (#2921), 11/2008.
36. Kurtova A, Quiroga M, Wierda W, Keating M, Burger JA. Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to Assess Cell Adhesion-Mediated Drug Resistance. Blood (ASH Annual Meeting Abstracts) 112 (#3149), 11/2008.
37. Cortes J, O'Brien S, Ferrajoli A, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). 2008 ASCO Annual Meeting (#7016), 5/2008.
38. Mattiuzzi G, Cortes J, Cassat J, Blamble D, Bekele B, Beran M, Borthakur G, Ravandi F, Burger JA, Kantarjian H. An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC). 2007 ASH Annual Meeting & Exposition (#2840), 11/2007.
39. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger JA, Verstovsek S, Garcia-Manero G, Cortes J. Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2. 2007 ASH Annual Meeting & Exposition (#1939), 11/2007.
40. Quintás-Cardama A, Kantarjian H, Ravandi F, Burger JA, Borthakur G, Cortes J. Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy. 2007 ASH Annual Meeting & Exposition (#2958), 11/2007.
41. Quiroga M, Henneberg M, Niedermeier M, Burger JA. CD62L (L-Selectin), CXCR4, CD49d, and CD38 Contribute to Migration of Chronic Lymphocytic B Cells Beneath Marrow Stromal Cells. 2007 ASH Annual Meeting & Exposition (#1119), 11/2007. PMID: 19318683.
42. Jabbour E, Kantarjian H,Jones D, O’Brien S,Garcia-Manero G, Burger JA, Cortes J. Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs). 2007 ASH Annual Meeting & Exposition (#1949), 11/2007.
43. Wierda W, O’Brien S, Faderl S, Ferrajoli A, Garcia-Manero G, Burger JA, Schlette E, Abruzzo L, Lerner S, Keating M. Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. 2007 ASH Annual Meeting & Exposition (#2065), 11/2007.
44. Cortes J,O’Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). 2007 ASH Annual Meeting & Exposition (#2481), 11/2007.
45. Burger JA, M Niedermeier , Bürkle A, Hartmann E, Wierda W, Keating M, Rosenwald A. High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Co-Cultures and in Response to BCR Stimulation. 2007 ASH Annual Meeting & Exposition (#342), 11/2007.
46. Jain N, Kantarjian H, Fava C, Thomas D, Burger JA, Borthakur G, Pate O, Cortes J. Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib. 2007 ASH Annual Meeting & Exposition (#1043), 11/2007.
47. Niedermeier M, Rawluk J, Knight Z, Shokat K, Wierda W, Keating M, Burger JA. Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications. 2007 ASH Annual Meeting & Exposition (#1125), 11/2007.
48. Ravandi F, Faderl S, Thomas D, Burger JA, Koller C, Garcia-Manero G, Morris G, Torma R, Kantarjian H, Issa J. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. 2007 ASH Annual Meeting & Exposition (#897), 11/2007.
49. Faderl S, Thomas D, Gandhi V, Borthakur G, Huang X, Plunkett W, Burger JA, Cortes J, O’Brien S, Ravandi F, Bretz J, Kwari M, Kantarjian H. Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). 2007 ASH Annual Meeting & Exposition (#4335), 11/2007.
50. Tam C, Thomas D, Ravandi F, Richardson C, Borthakur G, Burger JA, Estey E, Kantarjian H, Verstovsek S. Phase II Evaluation of Sunitinib Malate, a Multi-Targeted Inhibitor of Receptor Tyrosine Kinases, in Patients with Myelofibrosis. 2007 ASH Annual Meeting & Exposition (#3552), 11/2007.
51. Alvarado Y, Kantarjian H, Faderl S, Burger JA,Borthakur G, O’Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). 2007 ASH Annual Meeting & Exposition (#1932), 11/2007.
52. Delmonte, Jr, J, Kantarjian H, Estey E, Ravandi F, Borthakur G, Burger JA, Pierce S, Cortes J. Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia. 2007 ASH Annual Meeting & Exposition (#3505), 11/2007.
53. Ravandi F, Verstovsek S, Estrov Z, Burger JA, George S, Bivens, C, Cortes-Franco J, Garrett W, Newton R, Kantarjian, H. Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study. Blood (ASH Meeting Abstracts) (#631), 12/2006.
54. Burger JA, Borthakur G, Pierce S, Kantarjian H, Estey E. Reproducibility of diagnosis in patients with myelodysplastic syndrome. 2006 ASCO Annual Meeting Vol 24, No. 18S (#16506), 6/2006.
55. Hartmann TN, Krome M, Burger JA. B-cell receptor signaling enhances migration of B-cell chronic lymphocytic leukemia cells in response to the chemokine stromal cell-derived factor-1 (SDF-1/CXCL12). Blood 106(11):347a Part 1, 2005.
56. Bürkle A, Burger JA. Overexpression of the CXCR5 Chemokine Receptor, and its ligand, B cell-activating chemokine-1 (BCA-1/CXCL13) in B cell chronic lymphocytic leukemia. Blood 106(11):824a Part 1, 2005.
57. Hartman T, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 and Integrin Signaling Lead to Higher Resistance to Chemotherapy Induced Apoptosis in Small Cell Lung Cancer (SCLC). Onkologie 27(Suppl.3):35, 2004.
58. Bürkle A, Schmitt-Gräff A, Krome M, Behringer D, Burger JA. Expression and function of the CXCR5 chemokine receptor on B lymphocytes from patients with B cell chronic lymphocytic leukemia and other B cell neoplasias. Supplement to The Hematology Journal, 9th Annual Congress of EHA, Geneva, 2004.
59. Berg T, Filegauf M, Pitako J, Burger JA, Abdelkarim M, Guo Y, Staege MS, Burdach S, Lübbert M. Induction of G1 Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: p53-Independent Upregulation of p21/WAF/CIPI1. Blood 104(11):2576a, 2004.
60. Bert T, Filegauf M, Pitako J, Burger JA, Abdelkarim M, Guo Y, Staege MS, Burdach S, Lubbert M. Induction of GI Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: p53-Independent Upregulation of p21/WAF/CIPI1. Blood 104(11):2576a, 2004.
61. Burger M, Hartmann T, Burger JA, Ingrid U. Schraufstatter. KSHV-GPCR and CXCR2 Transforming Capacity and Angiogenic Responses Are Mediated through a JAK2-STAT3 Dependent Pathway. Blood 104(11), 2004.
62. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPRC and CXCR2 Transforming Capacity and Angiogenic Responses are Mediated Through a JAK2-STAT3 Dependent Pathway. Onkologie 27(Suppl.3):164, 2004.
63. Spoo AC, Wierda WG, Burger JA. The CXCR4 Score: A New Prognostic Marker in Acute Myelogenous Leukemia. Blood 104(11):1072a, 2004.
64. Burger M, Hartmann T, Fujii N, Kipps TJ, Burger JA. CXCR4 chemokine receptor antagonists inhibit activation, migration, and survival of chronic lymphocytic leukemia B cells in response to stromal cell-derived factor-1 (SDF-1/CXCL12). Blood 102(11):1585a, 2003.
65. Zeiser R, Burger JA, Bley T, Windfuhr-Blum M, Schulte-Mönting J, Behringer D. Immunocytology of the cerebral spinal fluid as compared to magnetic resonance imaging in the diagnosis of leptomeningeal metastasis-a retrospective analysis. Onkologie 26(Suppl 5):224, 2003.
66. Rawluk J, Burger M, Burger JA. Signal transduction pathways of the CXCR4 chemokine receptor for migration and apoptosis of chronic lymphocytic leukemia B cells. Blood 102(11):1576a, 2003.
67. Rawluk J, Burger M, Burger JA. Signal transduction pathways of the Cxcr4 chemokine receptor for migration and apoptosis of chronic lymphocytic leukemia B-cells. Onkologie 26(Suppl 5):167, 2003.
68. Burger M, Schmitt-Gräff A, Glodek A, Silberstein LE, Tsukada N, Kipps TJ, Burger JA. CXCR4 chemokine receptors target small cell lung cancer metastasis to the bone marrow. Onkologie 25(Suppl 4):139, 2002.
69. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H. Expression of functional CCR-and CXCR chemokine receptors in podocytes. J Am Soc Nephrol 13(Suppl S):349A, 2002.
70. Burger JA, Bürkle A, Behringer D. The chemokine B cell-activating chemokine-1 (BCA-1/CXCL13) is a powerful chemoattractant for chronic lymphocytic leukemia B cells. Onkologie 25(Suppl 4):173, 2002.
71. Burger JA, Burkle A, Behringer D. B cell chronic lymphocytic leukemia cells express functional CXCR5 chemokine receptors for the chemokine B cell-activating chemokine-1 (BCA-1/CXCL13). Blood 98(11):639a, 2001.
72. Burger JA, Tsukada N, Kipps TJ, Burger M. CXCR4 chemokine receptors target small cell lung cancer metastasis to the bone marrow. Blood 98(11):1239a, 2001.

Book Chapters

1. Burger JA. Mechanisms of leukemia cell trafficking, homing, and tissue retention in chronic lymphocytic leukemia. In: Hematology Education, Program for the 16th Congress of the European Hematology Association. 5, 1, 91-99, 2011.
2. Burger JA. Chronic Lymphocytic Leukemia (CLL). In: Hematology und Internistische Onkologie, 3. Ed(s) DP Berger, R Engelhardt, R Mertelsmann. Das Rote Buch: Germany, 2006.

Letters to the Editor

1. Ponader S, Burger JA. Modeling the marrow stem cell niche in vitro: is proximity the key to reproduction? Haematologica 95(9):e5, 9/2010. PMCID: PMC2930977.

Grant & Contract Support

Title: Understanding and overcoming mutant p53 mediated resistance in CLL
Funding Source: CLL Global Research Foundation
Role: Co-Investigator
Principal Investigator: Alfonso Quintas-Cardama, MD
Duration: 5/2/2013 - 5/1/2014
 
Title: Chronic Lymphocytic Leukemia Research Consortium Project 3 "Immune Therapy"
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Thomas Kipps, MD
Duration: 9/24/2012 - 8/31/2017
 
Title: Chronic Lymphocytic Leukemia Research Consortium: Project 2: Biochemistry of apoptosis in CLL
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Thomas Kipps, M.D.
Duration: 9/24/2012 - 8/31/2017
 
Title: Targeting Microenvironment-Related Resistance in adult acute lymphoblastic leukemia (ALL) chemokine receptor: a new approach to overcome stromal cell-mediated drug resistance in Acute Lymphoblastic Leukemia (ALL)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 7/1/2011 - 12/30/2014
 
Title: Analysis of post treatment samples of PCI 32765
Funding Source: Pharmacyclics
Role: Principal Investigator
Duration: 6/3/2010 - 6/30/2015
 
Title: Dissecting the molecular pathways for cross-talk between Chronic Lymphocytic Leukemia cells and their microenvironment. 2. Effects of co-culture of CLL B cells with different stromal cells on sensitivity to anti-CLL drugs: towards a standardized assays to analyze cell adhesion-mediated drug-resistance
Funding Source: CLL Global Research Foundation
Role: Principal Investigator
Duration: 3/7/2008 - 8/31/2013
 
Title: Career Development Award: Improvement of current therapies with forodesine and fludarabine in chronic lymphocytic leukemia (CLL) by targeting the leukemia microenvironment
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2007 - 6/30/2011
 
Title: ASH Basic Research Scholar Award : The CXCR4 Chemokine Receptor: a New Prognostic Marker and Therapeutic Target in Acute Myelogenous Leukemia
Funding Source: American Society of Hematology (ASH)
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2008
 
Title: "Anatomy of the microenvironment in Chronic Lymphocytic Leukemia: focus on the chemokine CXCL13". New Investigator Grant.
Funding Source: Leukemia Research Foundation, Chicago, IL.
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2008
 
Title: Kimmel Scholar Award
Funding Source: Sidney Kimmel Foundation for Cancer Research
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2008
 
Title: Young Investigator Award: Targeting CXCR4 chemokine receptors and VLA-4 integrins in B cell lymphoid leukemias
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2007
 
Title: Microenvironmental regulation of survival and growth of B lymphocytes from patients with chronic lymphocytic leukemia (CLL)
Funding Source: CLL Global Research Foundation, Houston, Texas
Role: Principal Investigator
Duration: 12/29/2005 - 11/30/2008
 
Title: Expression and Function of the CXCR5 Chemokine Receptor, and its Ligand, CXCL13, in Chronic Lymphocytic Leukemia (CLL)
Funding Source: Lauri Strauss
Role: Principal Investigator
Duration: 1/1/2005 - 12/31/2005
 
Title: CXCR4 chemokine receptor antagonists for the treatment of chronic lymphocytic leukemia (CLL).
Funding Source: Jose Carreras Leukemia Society, Munich, Germany
Role: Principal Investigator
Duration: 9/1/2002 - 12/31/2006
 
Title: CXCR4 chemokine receptor signal transduction pathways in chronic lymphocytic leukemia (CLL).
Funding Source: Deutsche Krebshilfe, Bonn, Germany
Role: Principal Investigator-MDACC
Duration: 9/1/2001 - 3/30/2005

Last updated: 5/28/2014